Sean M. Healey & AMG Center for ALS
Healey ALS MyMatch
Sean M. Healey & AMG Center for ALS at Mass General
165 Cambridge Street, 6th floor
Boston,
MA
02114
Explore This Program
Overview
The goal of the Healey ALS MyMatch program is to accelerate the development of new therapies for ALS. ALS MyMatch is a series of early-phase (Phase 1b/2a) clinical trials. These trials assess a range of investigational products, including experimental and repurposed medications, cell-based therapies, gene-targeted therapies, devices, etc. Participants are matched to specific trials based on their own genetic and biofluid biomarkers, placing participants at the center of the research process. By prioritizing high quality biomarker data in early-phase clinical trials, ALS MyMatch paves the way for faster advancements in treatment.
Launched in 2025, this collaborative ALS MyMatch initiative was made possible through generous philanthropic support to the Sean M. Healey & AMG Center for ALS at Mass General Brigham. ALS MyMatch trials are conducted at multiple trial-ready U.S. ALS research and clinical care centers selected from the Network of Excellence for ALS (NEALS). Data generated from successful ALS MyMatch trials will inform future late phase clinical trial design via the HEALEY ALS Platform Trial or a standalone Phase 2/3 trial.
At the heart of ALS MyMatch lies the value of rigor and innovation to confidently answer critical scientific questions in early stages of drug development and thoughtfully inform future therapeutic development in ALS.
Principal Investigator of Healey ALS MyMatch
ALS MyMatch Trials
Future trials will be added as new investigational products become available.
ACACIA Trial of Oral Digoxin – Enrollment Complete
Visit ClinicalTrials.gov for information about study details and site locations (NCT07047209).
Community Webinars
We are committed to an ongoing dialogue with the entire ALS community. Register to attend upcoming Healey ALS MyMatch community Q&A webinars or view previous recordings.
Webinar Recordings
December 10, 2025: Everything ALS Webinar - Healey ALS MyMatch: Overview & Update
Suma Babu, MBBS, MPH of Massachusetts General Hospital presented an overview of the ALS MyMatch program and provided updates on the first trial.
Watch recording
June 9, 2025: NEALS Webinar – ACACIA Trial of Oral Digoxin in ALS
Suma Babu, MBBS, MPH and Brian Wainger, MD, PhD of Mass General Hospital presented information about the first Healey ALS MyMatch trial, the ACACIA Trial of Oral Digoxin in ALS, and answered questions from the audience.
Watch recording
June 5, 2025: ALS MyMatch Discussion with Dr. Suma Babu
Suma Babu, MBBS, MPH and Sabrina Paganoni, MD, PhD of Mass General Hospital presented an overview of Healey ALS MyMatch and answered questions from the audience.
Watch recording
Researcher Resources
Healey ALS MyMatch is designed to support biomarker-driven Phase 1b/2a clinical trials in ALS. The Sean M. Healey & AMG Center for ALS is seeking applications of experimental therapies for inclusion in this clinical trial initiative on a rolling basis. ALS MyMatch trials are best suited for therapies focused on biological efficacy, target engagement, CNS penetrance, pharmacokinetics and/or dose finding. We invite investigators from both academia and industry to apply for consideration in ALS MyMatch.
Confidential Disclosure Agreements (CDAs) are executed between MGH and the institution or company before the ALS MyMatch Therapy Application Form is submitted.
Download the CDA template (Word document)
In the News
- November 25, 2025: Selection of Tiziana Life Sciences to Enter ALS MyMatch – Read the release
- November 13, 2025: Design Announcement with Inflammasome Therapeutics for ALS MyMatch – Read the release
- October 29, 2025: Enrollment Completion for First ALS MyMatch Trial – Read the release
- February 25, 2025: Launch of ALS MyMatch – Read the release
Support ALS MyMatch
Whether you’re looking to collaborate with the Healey Center, interested in participating in ALS MyMatch, or passionate about supporting ALS research, we look forward to partnering with you.